These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28870516)

  • 1. A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome.
    Watanabe H; Watanabe Y; Tashiro Y; Mushiroda T; Ozeki T; Hashizume H; Sueki H; Yamamoto T; Utsunomiya-Tate N; Gouda H; Kusakabe Y
    J Dermatol Sci; 2017 Dec; 88(3):320-329. PubMed ID: 28870516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.
    Liu H; Wang Z; Bao F; Wang C; Sun L; Zhang H; Yu G; Mi Z; Li J; Li L; Zhao Q; Yue Z; Zhao W; Yu W; Cao J; Xiong F; Wang Y; Chai Z; Cheng X; Zhang Y; Fu F; Lang X; Wang X; Irwanto A; Krismawati H; Fu X; Sun Y; You J; Liu J; Pan Q; Chu T; Liu D; Chen S; Shen J; Yan L; Zhang G; Liu J; Zhang F; ; Xiong L; Yang J; Li J; Ke W; Li M; Ning Y; Xiong J; Li M; Xiong M; Yang B; Duan Q; Wang H; Li W; Kuang Y; Li J; Wang L; Cao Q; Xiao P; Xiao B; Zhang L; Lin Z; Wang Y; Shen Y; Yan L; Wu W; Zheng H; Zhan X; Li W; Shang X; Xu Y; Liu Q
    JAMA Dermatol; 2019 Jun; 155(6):666-672. PubMed ID: 30916737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia.
    Krismawati H; Irwanto A; Pongtiku A; Irwan ID; Maladan Y; Sitanggang YA; Wahyuni T; Tanjung R; Sun Y; Liu H; Zhang F; Oktavian A; Liu J
    PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008746. PubMed ID: 33064728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-B*13:01 and the dapsone hypersensitivity syndrome.
    Zhang FR; Liu H; Irwanto A; Fu XA; Li Y; Yu GQ; Yu YX; Chen MF; Low HQ; Li JH; Bao FF; Foo JN; Bei JX; Jia XM; Liu J; Liany H; Wang N; Niu GY; Wang ZZ; Shi BQ; Tian HQ; Liu HX; Ma SS; Zhou Y; You JB; Yang Q; Wang C; Chu TS; Liu DC; Yu XL; Sun YH; Ning Y; Wei ZH; Chen SL; Chen XC; Zhang ZX; Liu YX; Pulit SL; Wu WB; Zheng ZY; Yang RD; Long H; Liu ZS; Wang JQ; Li M; Zhang LH; Wang H; Wang LM; Xiao P; Li JL; Huang ZM; Huang JX; Li Z; Liu J; Xiong L; Yang J; Wang XD; Yu DB; Lu XM; Zhou GZ; Yan LB; Shen JP; Zhang GC; Zeng YX; de Bakker PI; Chen SM; Liu JJ
    N Engl J Med; 2013 Oct; 369(17):1620-8. PubMed ID: 24152261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions.
    Chen WT; Wang CW; Lu CW; Chen CB; Lee HE; Hung SI; Choon SE; Yang CH; Liu MT; Chen TJ; Fan WL; Su SC; Lin YY; Chang YC; Chung WH;
    J Invest Dermatol; 2018 Jul; 138(7):1546-1554. PubMed ID: 29458119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses.
    Park HJ; Park JW; Kim SH; Choi SY; Kim HK; Jung CG; Yang MS; Kang DY; Cho MK; Kwon HS; Kang HR; Lee YW;
    Expert Opin Drug Saf; 2020 Oct; 19(10):1349-1356. PubMed ID: 32700588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal dapsone hypersensitivity syndrome with hypothyroidism and steroid-induced diabetes mellitus.
    Pai S; Munshi R; Nayak C
    Indian J Pharmacol; 2017; 49(5):396-398. PubMed ID: 29515281
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Satapornpong P; Pratoomwun J; Rerknimitr P; Klaewsongkram J; Nakkam N; Rungrotmongkol T; Konyoung P; Saksit N; Mahakkanukrauh A; Amornpinyo W; Khunarkornsiri U; Tempark T; Wantavornprasert K; Jinda P; Koomdee N; Jantararoungtong T; Rerkpattanapipat T; Wang CW; Naisbitt D; Tassaneeyakul W; Ariyachaipanich M; Roonghiranwat T; Pirmohamed M; Chung WH; Sukasem C
    Front Immunol; 2021; 12():661135. PubMed ID: 34017337
    [No Abstract]   [Full Text] [Related]  

  • 9. Dapsone: An Update.
    Karjigi S; Murthy SC; Kallappa H; Kusuma MR; Aruna B; Reddy YN
    Indian J Lepr; 2016 Sep; 87(4):233-239. PubMed ID: 29762952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China.
    Wang H; Yan L; Zhang G; Chen X; Yang J; Li M; Shen J; Yu M; Huo R; Wang B
    J Invest Dermatol; 2013 Nov; 133(11):2642-2644. PubMed ID: 23604100
    [No Abstract]   [Full Text] [Related]  

  • 11. A Review on Dapsone Hypersensitivity Syndrome Among Chinese Patients with an Emphasis on Preventing Adverse Drug Reactions with Genetic Testing.
    Wang N; Parimi L; Liu H; Zhang F
    Am J Trop Med Hyg; 2017 May; 96(5):1014-1018. PubMed ID: 28167593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapsone hypersensitivity syndrome among leprosy patients in China.
    Tian W; Shen J; Zhou M; Yan L; Zhang G
    Lepr Rev; 2012 Dec; 83(4):370-7. PubMed ID: 23614255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Th17 Response of Borderline-Lepromatous Leprosy Inhibits Rash Manifestation of Dapsone Hypersensitivity Syndrome: Case Report.
    de Nardo Vanzela T; Bernardes Filho F; Wambier CG; Faria FM; Foss NT; Frade MAC
    Am J Dermatopathol; 2018 Mar; 40(3):205-208. PubMed ID: 28937434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAP2 Drives HLA-B∗13:01‒Linked Dapsone Hypersensitivity Syndrome Tolerance and Reactivity.
    Sun L; Wang Z; Liu T; Zhao Q; Yu G; Sun Y; Xue X; You J; Yue Z; Mi Z; Liu H; Zhang F
    J Invest Dermatol; 2023 May; 143(5):722-730.e1. PubMed ID: 37306379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal.
    Pandey B; Shrestha K; Lewis J; Hawksworth RA; Walker SL
    Trop Doct; 2007 Jul; 37(3):162-3. PubMed ID: 17716505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular docking and simulation study for synthesis of alternative dapsone derivative as a newer antileprosy drug in multidrug therapy.
    Swain SS; Paidesetty SK; Dehury B; Sahoo J; Vedithi SC; Mahapatra N; Hussain T; Padhy RN
    J Cell Biochem; 2018 Dec; 119(12):9838-9852. PubMed ID: 30125973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of genetic screening test to reduce the incidence of dapsone hypersensitivity syndrome among patients with leprosy in Papua, Indonesia: a study protocol.
    Krismawati H; Ferdiana A; Irwanto A; Budiawan T; Imaniar C; Wahyuni T; Singh P; Mieras L; Pongtiku A
    BMJ Open; 2022 May; 12(5):e057173. PubMed ID: 35545382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population.
    Tempark T; Satapornpong P; Rerknimitr P; Nakkam N; Saksit N; Wattanakrai P; Jantararoungtong T; Koomdee N; Mahakkanukrauh A; Tassaneeyakul W; Suttisai S; Pratoomwun J; Klaewsongkram J; Rerkpattanapipat T; Sukasem C
    Pharmacogenet Genomics; 2017 Dec; 27(12):429-437. PubMed ID: 28885988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of dapsone hypersensitivity syndrome in an Indian leprosy patient: Retrospective screening reveals the genetic connection with HLA-B*13:01.
    Bommakanti J; Namoju R; Jabeen T; Mohammed AK; Kothakoti G; Pashikanti S; Chilaka NK; Avanapu SR
    Dermatol Ther; 2020 Nov; 33(6):e13825. PubMed ID: 32535989
    [No Abstract]   [Full Text] [Related]  

  • 20. Increase in the incidence of dapsone hypersensitivity syndrome--an appraisal.
    Rao PN; Lakshmi TS
    Lepr Rev; 2001 Mar; 72(1):57-62. PubMed ID: 11355519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.